<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260714</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02559</org_study_id>
    <secondary_id>NCI-2011-02559</secondary_id>
    <secondary_id>CDR0000690647</secondary_id>
    <secondary_id>PHL-074</secondary_id>
    <secondary_id>8331</secondary_id>
    <secondary_id>N01CM00032</secondary_id>
    <secondary_id>N01CM62203</secondary_id>
    <nct_id>NCT01260714</nct_id>
  </id_info>
  <brief_title>Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age â‰¥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the best dose of azacitidine and to see how well it works with&#xD;
      mitoxantrone hydrochloride and etoposide in treating older patients with acute myeloid&#xD;
      leukemia that has a lower chance of responding to treatment or higher risk of returning (poor&#xD;
      prognosis). Drugs used in chemotherapy, such as azacitidine, mitoxantrone hydrochloride, and&#xD;
      etoposide, work in different ways to stop the growth of cancer cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)&#xD;
      may kill more cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the highest tolerated dose of two dosing schedules of azacitidine when&#xD;
      combined with mitoxantrone (mitoxantrone hydrochloride) and etoposide (A-NOVE) chemotherapy&#xD;
      in poor prognosis older patients with acute myeloid leukemia (AML).&#xD;
&#xD;
      II. To evaluate the toxicity of this regimen.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the complete response (CR) rate and using this regimen. II. To evaluate&#xD;
      changes in topoisomerase II activity, deoxyribonucleic acid (DNA) methylation and DNA&#xD;
      expression arrays in leukemia cells during azacitidine treatment, and to correlate these&#xD;
      changes with responses to A-NOVE chemotherapy.&#xD;
&#xD;
      III. To evaluate relapse-free survival (RFS) and overall survival (OS) in patients receiving&#xD;
      post-remission consolidation with A-NOVE in patients achieving CR. (OS follow-up discontinued&#xD;
      as of 08/07/2014)&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of azacitidine.&#xD;
&#xD;
      Patients receive induction therapy comprising azacitidine subcutaneously (SC) once daily (QD)&#xD;
      on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on&#xD;
      days 4-8. Patients may receive up to 2 additional courses of the same treatment as&#xD;
      re-induction or consolidation therapy beginning 35-60 days from the start of the previous&#xD;
      course.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate accrual rate&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose of azacitidine that can be safely combined with mitoxantrone hydrochloride and etoposide chemotherapy</measure>
    <time_frame>Up to 2 courses of treatment</time_frame>
    <description>The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in DNA methylation</measure>
    <time_frame>Baseline to day 4</time_frame>
    <description>Nonquantitative comparisons will be made between responders and non-responders with respect to changes in DNA methylation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression</measure>
    <time_frame>Baseline to day 4</time_frame>
    <description>Nonquantitative comparisons will be made between responders and non-responders with respect to changes in gene expression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in topoisomerase II levels</measure>
    <time_frame>Baseline to day 4</time_frame>
    <description>These will be compared between responders (i.e. those achieving either CR or morphologic leukemia-free state [MLFS]) vs. non-responders (those not achieving CR/MLFS after 1-2 induction cycles), with 95% confidence intervals and 2-tailed t-tests of significance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the start of study treatment until death from any cause or last follow up, assessed up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>From documentation of CR or MLFS to time of disease recurrence or last follow up, assessed up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Basophilic Leukemia</condition>
  <condition>Adult Acute Eosinophilic Leukemia</condition>
  <condition>Adult Acute Megakaryoblastic Leukemia</condition>
  <condition>Adult Acute Monoblastic Leukemia</condition>
  <condition>Adult Acute Monocytic Leukemia</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With Maturation</condition>
  <condition>Adult Acute Myeloid Leukemia With Minimal Differentiation</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1</condition>
  <condition>Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL</condition>
  <condition>Adult Acute Myeloid Leukemia Without Maturation</condition>
  <condition>Adult Acute Myelomonocytic Leukemia</condition>
  <condition>Adult Erythroleukemia</condition>
  <condition>Adult Pure Erythroid Leukemia</condition>
  <condition>Alkylating Agent-Related Acute Myeloid Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Secondary Acute Myeloid Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)</arm_group_label>
    <other_name>CL 232315</other_name>
    <other_name>DHAD</other_name>
    <other_name>DHAQ</other_name>
    <other_name>Dihydroxyanthracenedione Dihydrochloride</other_name>
    <other_name>Mitoxantrone Dihydrochloride</other_name>
    <other_name>Mitoxantroni Hydrochloridum</other_name>
    <other_name>Mitozantrone Hydrochloride</other_name>
    <other_name>Mitroxone</other_name>
    <other_name>Neotalem</other_name>
    <other_name>Novantrone</other_name>
    <other_name>Onkotrone</other_name>
    <other_name>Pralifan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia (AML) as defined by World Health Organization (WHO) criteria,&#xD;
             any subtype, de novo or secondary, except acute promyelocytic leukemia (APL)&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
               -  Previously untreated, with adverse-risk cytogenetics, including any one of the&#xD;
                  following:&#xD;
&#xD;
                    -  Complete or partial deletion of chromosome 7&#xD;
&#xD;
                    -  Complete or partial deletion of chromosome 5&#xD;
&#xD;
                    -  At least 3 numerical or structural abnormalities, other than t(15;17),&#xD;
                       t(8;21) or inv(16) or variant&#xD;
&#xD;
                    -  11q23 abnormalities&#xD;
&#xD;
                    -  Inv(3) or variant such as t(3:3)&#xD;
&#xD;
               -  Previously untreated, transformed from prior myelodysplastic syndrome (MDS) or&#xD;
                  myeloproliferative disorder (MPD) other than CML&#xD;
&#xD;
               -  Persistent leukemia following one cycle of 3+7 induction therapy (cytarabine plus&#xD;
                  either daunorubicin or idarubicin), any cytogenetic risk group&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt; 50% based on multi gated acquisition scan&#xD;
             (MUGA) scan or 2-dimensional (2-D) echocardiogram&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum bilirubin =&lt; 1.5 x ULN&#xD;
&#xD;
          -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Patients with high initial white blood cell (WBC) should have the WBC reduced to below&#xD;
             50 x 10^9/L with hydroxyurea, to minimize the risk of leukostasis&#xD;
             related-complications; hydroxyurea is permitted up to 24 hours prior to starting&#xD;
             azacitidine&#xD;
&#xD;
          -  Men must agree to use adequate contraception (hormonal or barrier method of birth&#xD;
             control; abstinence) prior to study entry and for the duration of study participation;&#xD;
             men should not father a child while participating in this study&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy, radiotherapy or investigational agents within 4&#xD;
             weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those&#xD;
             who have not recovered from adverse events due to agents administered more than 4&#xD;
             weeks earlier&#xD;
&#xD;
          -  Patients who have received prior radiation greater than 3000 cGy to marrow producing&#xD;
             areas&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents&#xD;
&#xD;
          -  Patients with active central nervous system (CNS) leukemia; prior CNS leukemia is&#xD;
             permitted provided the cerebrospinal fluid has cleared and there is no other evidence&#xD;
             of active CNS leukemia&#xD;
&#xD;
          -  Prior therapy for AML with decitabine, azacitidine, mitoxantrone, or etoposide&#xD;
&#xD;
          -  Prior therapy with azacitidine or decitabine for pre-existing MDS&#xD;
&#xD;
          -  History of allergic reactions attributed to decitabine, azacitidine, etoposide,&#xD;
             mitoxantrone, or compounds of similar chemical or biologic composition&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, active uncontrolled&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients with cluster of differentiation&#xD;
             (CD) counts less than 500/mm^3 and/or a history of HIV/acquired immune deficiency&#xD;
             syndrome (AIDS)-related complications will be excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Brandwein</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network-Princess Margaret Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Basophilic, Acute</mesh_term>
    <mesh_term>Leukemia, Eosinophilic, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

